Tom Powles: First-Line UC Trials – Ipi/Nivo Fails on OS, Durva/Treme Shows Potential in PD-L1 Positive Patients
Tom Powles, Director of Barts Cancer Centre, shared a post on X:
“Just out. Ipi/nivo didn’t hit OS in cisplatin ineligible or PD-L1 +ve in 1st line UC in CM901.
Surprising? Durva/treme (also -ve) had activity, especially in PD-L1 +ves (HR 0.74, CI 0.6-0.9-not stat tested). Different PD-L1 biomarkers used.
Data awaited.”
More posts featuring Tom Powles.
Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre.
With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals. His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023